Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Kane Biotech Inc

Healthcare CA KNE

0.03CAD
0.00(0%)

Last update at 2026-06-22T17:10:00Z

Day Range

0.030.03
LowHigh

52 Week Range

0.030.10
LowHigh

Fundamentals

  • Previous Close 0.03
  • Market Cap5.86M
  • Volume2000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.72393M
  • Revenue TTM0.57M
  • Revenue Per Share TTM0.003
  • Gross Profit TTM -0.09541M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -4.47135M -4.56234M -3.82400M -4.84991M -3.84598M
Minority interest -0.06832M 0.17M -0.06589M 0.25M 2.56M
Net income 6.10M -5.03410M -3.88989M -4.60457M -3.71669M
Selling general administrative 3.08M 3.78M 3.72M 4.07M 3.43M
Selling and marketing expenses - - - - -
Gross profit 0.87M -0.12912M 1.41M 0.57M 0.53M
Reconciled depreciation 0.22M 0.26M 0.26M 0.19M 0.08M
Ebit - -3.82310M -3.00287M -4.43783M -3.72602M
Ebitda - -3.58451M -2.74519M -4.24986M -3.64791M
Depreciation and amortization - 0.24M 0.26M 0.19M 0.08M
Non operating income net other - - - - -
Operating income -3.92300M -3.82310M -3.36381M -4.88356M -4.22437M
Other operating expenses - 3.97M 6.03M 6.49M 5.57M
Interest expense 0.55M 1.22M 0.82M 0.42M 0.12M
Tax provision -1.31026M - - - -
Interest income 0.00494M 0.07M 0.10M 0.12M 0.04M
Net interest income -0.54054M -1.16629M -0.72186M -0.29413M -0.08326M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.47M 1.14M 0.49M 0.45M
Total revenue 2.08M 0.15M 2.67M 1.61M 1.34M
Total operating expenses 6.00M 3.69M 4.78M 5.45M 4.75M
Cost of revenue 1.21M 0.28M 1.26M 1.04M 0.81M
Total other income expense net -0.00782M -0.73925M 0.26M 0.33M 0.46M
Discontinued operations - - - - -
Net income from continuing ops -3.16110M -4.49631M -3.82400M -4.84991M -3.84598M
Net income applicable to common shares - - -3.88989M -4.60457M -3.71669M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 2.49M 5.68M 5.62M 6.13M 5.04M
Intangible assets 0.54M - 0.83M 0.83M 0.78M
Earning assets - - - - -
Other current assets 0.21M 2.62M 0.17M 0.14M 0.14M
Total liab 4.12M 14.09M 9.76M 7.70M 3.96M
Total stockholder equity -1.62924M -10.55830M -6.52257M -3.88598M -1.48958M
Deferred long term liab - - - - -
Other current liab 0.12M 2.67M 0.21M 1.58M 0.68M
Common stock - 23.69M 23.13M 22.16M 20.86M
Capital stock 24.40M - 23.13M 22.16M 20.86M
Retained earnings -34.41513M -42.13428M -37.10017M -33.21028M -28.60572M
Other liab - - 0.84M 0.78M 0.35M
Good will - - - - -
Other assets - - 0.44M 0.99M 1.36M
Cash 0.36M 0.75M 1.10M 1.15M 1.01M
Cash and equivalents - - - - -
Total current liabilities 2.41M 10.89M 6.34M 4.72M 2.92M
Current deferred revenue - 0.75M - - -
Net debt 0.94M 8.46M 4.66M 2.34M 1.16M
Short term debt - 7.04M - - -
Short long term debt 0.34M - 4.17M 2.38M 1.51M
Short long term debt total - 9.21M - - -
Other stockholder equity - 7.75M - 1.66M 1.84M
Property plant equipment - - 1.25M 1.44M 0.16M
Total current assets 1.03M 3.72M 3.10M 2.88M 2.74M
Long term investments - - - - -
Net tangible assets - - -7.34903M -4.71463M -2.26650M
Short term investments - - - - -
Net receivables 0.01M 0.10M 1.06M 1.07M 1.12M
Long term debt 0.96M - 1.60M 1.12M 0.66M
Inventory 0.38M 0.25M 0.76M 0.52M 0.47M
Accounts payable 1.19M 0.44M 1.85M 0.63M 0.66M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.14M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.89M - - -
Deferred long term asset charges - - - - -
Non current assets total 1.47M 1.96M 2.52M 3.25M 2.30M
Capital lease obligations 0.87M - 1.09M 1.22M 0.08M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 10.27M -0.11552M -0.10755M -0.37355M -0.16611M
Change to liabilities - - -0.08565M 1.29M -0.01811M
Total cashflows from investing activities - - -0.10755M -0.37355M -0.16611M
Net borrowings -6.65468M - 2.25M 1.25M 2.35M
Total cash from financing activities -6.99736M 2.98M 3.10M 2.81M 4.28M
Change to operating activities - - -0.03380M 0.00626M -0.08674M
Net income 6.10M -4.56234M -3.82400M -4.84991M -3.84598M
Change in cash -1.52991M -0.35565M -0.04819M 0.15M 0.17M
Begin period cash flow 1.14M 1.10M 1.15M 1.01M 0.83M
End period cash flow 0.36M 0.75M 1.10M 1.15M 1.01M
Total cash from operating activities -4.11135M -2.08215M -3.04347M -2.28919M -3.93897M
Issuance of capital stock 0.00000M 0.42M 0.97M 0.00000M 0.70M
Depreciation 0.22M 0.24M 0.26M 0.19M 0.08M
Other cashflows from investing activities - - -0.02000M -0.02000M -0.04000M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory -0.12562M -0.11347M -0.24424M -0.04729M 0.12M
Change to account receivables - 0.00582M -0.01468M 0.04M -0.27849M
Sale purchase of stock - - - - -
Other cashflows from financing activities - 0.47M 2.66M 2.23M 3.60M
Change to netincome - - 0.78M 0.83M -0.03215M
Capital expenditures 0.09M 0.05M 0.09M 0.35M 0.13M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -5.83476M 0.59M -0.37838M 1.29M -0.26824M
Stock based compensation 0.71M 0.26M 0.28M 1.09M 0.46M
Other non cash items 4.20M 2.04M 0.43M -0.07812M -0.40743M
Free cash flow -4.20148M -2.13188M -3.13102M -2.64274M -4.06508M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
KNE
Kane Biotech Inc		 - -% 0.03 - - 10.19 104.38 12.55 -6.1714
SHRX
Sharp Therapeutics Corp.		 - -% 1.00 - - - 32.37
NRX
NurExone Biologic Inc.		 -0.01 1.79% 0.55 - 6.90 - 15.26 -7.2365
MIR
MedMira Inc		 - -% 0.07 - - 223.37 - 293.42 -80.0318
TTI
Thiogenesis Therapeutics Corp.		 - -% 0.56 - - - 15.17 -58.1577

Reports Covered

Stock Research & News

View All

Profile

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio includes antimicrobial wound gel, antimicrobial wound gel spray, and antimicrobial wound rinse under revyve name, as well as antimicrobial surgical hydrogel under coactiv+ name. In addition, the company offers shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. Further, it engages in developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; revyve Antimicrobial Wound Rinse for use in acute and chronic wounds; DispersinB Hydrogel for use in surgical/acute wounds; and DispersinB Acne Cleanser for use in the treatment of mild to moderate Acne Vulgaris. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Kane Biotech Inc

290-100 Innovation Drive, Winnipeg, MB, Canada, R3T 6G2

Key Executives

Name Title Year Born
Mr. Marc Edwards Pres, CEO & Director NA
Mr. Ray Dupuis Chief Financial Officer NA
Mr. Kevin Cole Pres & CEO of STEM Animal Health Inc NA
Dr. Gregory S. Schultz Ph.D. Chief Scientific Officer & Member of Scientific Advisory Board 1950
Lorne Gorber Investor Relations NA
Ms. Lori Christofalos VP of Quality & Compliance NA
Ms. Wendy Nachtigall Director of Marketing NA
Nicole Sendey Investor Relations Adviser NA
Mr. Mark Ahrens-Townsend Advisor NA
Mr. Marc Edwards President, CEO & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.